论文部分内容阅读
目的探讨甘精胰岛素经皮超声导入的降糖效果。方法将43例T2DM患者随机分组,分别采用经皮超声导入甘精胰岛素和皮下注射甘精胰岛素两种不同方法控制血糖,自身前后交叉对照,评价经皮超声导入甘精胰岛素的降糖效果,比较不同给药方式所需的胰岛素剂量。结果甘精胰岛素采用经皮超声导入和皮下注射两种不同的给药方式,对空腹及餐后血糖的控制无统计学差异(P>0.05),不同给药方式所需甘精胰岛素剂量具有统计学差异(P<0.05)。结论经皮超声导入甘精胰岛素以及皮下注射甘精胰岛素两种给药方式均能有效控制血糖。在达到同样降糖目标的情况下,经皮超声导入所需甘精胰岛素剂量较皮下注射增多15%左右。
Objective To investigate the hypoglycemic effect of transnasal insulin glargine transdermally. Methods Forty-three patients with T2DM were randomly divided into two groups: control group, transcutaneous ultrasound with insulin glargine and insulin glargine subcutaneously, respectively, to control blood glucose and cross-control before and after transdermal ultrasound. The amount of insulin required for different modes of administration. Results The insulin glargine was administered by two different methods: transcutaneous ultrasound and subcutaneous injection. There was no significant difference in the control of fasting and postprandial blood glucose (P> 0.05). The dosage of insulin glargine required by different modes of administration was statistically Learning difference (P <0.05). Conclusion Both transdermal ultrasound-guided insulin glargine injection and insulin glargine subcutaneous injection can effectively control blood sugar. In achieving the same goal of hypoglycemic agents, percutaneous transdermal ultrasound insulin glargine required dose increased by about 15% compared with subcutaneous injection.